WO2001078760A3 - Method for treating pain by peripheral administration of a neurotoxin - Google Patents

Method for treating pain by peripheral administration of a neurotoxin Download PDF

Info

Publication number
WO2001078760A3
WO2001078760A3 PCT/US2001/011836 US0111836W WO0178760A3 WO 2001078760 A3 WO2001078760 A3 WO 2001078760A3 US 0111836 W US0111836 W US 0111836W WO 0178760 A3 WO0178760 A3 WO 0178760A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotoxin
peripheral administration
treating pain
treating
administration
Prior art date
Application number
PCT/US2001/011836
Other languages
French (fr)
Other versions
WO2001078760A2 (en
Inventor
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Original Assignee
Allergan Sales Inc
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24196890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001078760(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2001251546A priority Critical patent/AU2001251546B9/en
Priority to CA002406367A priority patent/CA2406367C/en
Priority to JP2001576060A priority patent/JP4037652B2/en
Priority to AU5154601A priority patent/AU5154601A/en
Priority to MXPA02009932A priority patent/MXPA02009932A/en
Application filed by Allergan Sales Inc, Kei Roger Aoki, Minglei Cui, Stephen Jenkins filed Critical Allergan Sales Inc
Priority to DE60128899T priority patent/DE60128899T2/en
Priority to NZ521535A priority patent/NZ521535A/en
Priority to EP01924939A priority patent/EP1272207B1/en
Priority to DK01924939T priority patent/DK1272207T3/en
Priority to BR0110030-0A priority patent/BR0110030A/en
Publication of WO2001078760A2 publication Critical patent/WO2001078760A2/en
Publication of WO2001078760A3 publication Critical patent/WO2001078760A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.
PCT/US2001/011836 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin WO2001078760A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR0110030-0A BR0110030A (en) 2000-04-14 2001-04-11 Method for treating pain through peripheral administration of a neurotoxin
CA002406367A CA2406367C (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin
JP2001576060A JP4037652B2 (en) 2000-04-14 2001-04-11 Pain treatment preparation containing neurotoxin
AU5154601A AU5154601A (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin
MXPA02009932A MXPA02009932A (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin.
AU2001251546A AU2001251546B9 (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin
DE60128899T DE60128899T2 (en) 2000-04-14 2001-04-11 USE OF A BOTULINUM TOXIN FOR THE MANUFACTURE OF A MEDICAMENT FOR PERIPHERAL TREATMENT OF PAIN NOT RELATED TO MUSCLE SPAS OR HEADACHE
NZ521535A NZ521535A (en) 2000-04-14 2001-04-11 Treatment of pain by peripheral administration of a medicament comprising the botulinum toxin
EP01924939A EP1272207B1 (en) 2000-04-14 2001-04-11 Use of a botulinum toxin for the manufacture of a medicament for peripheral administration for treating pain non associated to muscle spasm or headache
DK01924939T DK1272207T3 (en) 2000-04-14 2001-04-11 Use of a botulinum toxin for the manufacture of a drug for peripheral administration for the treatment of pain not associated with muscle spasm or headache

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/550,371 US6464986B1 (en) 2000-04-14 2000-04-14 Method for treating pain by peripheral administration of a neurotoxin
US09/550,371 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001078760A2 WO2001078760A2 (en) 2001-10-25
WO2001078760A3 true WO2001078760A3 (en) 2002-03-21

Family

ID=24196890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011836 WO2001078760A2 (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin

Country Status (19)

Country Link
US (14) US6464986B1 (en)
EP (7) EP1576963B1 (en)
JP (1) JP4037652B2 (en)
KR (1) KR20030009431A (en)
CN (1) CN1188165C (en)
AR (1) AR030209A1 (en)
AT (6) ATE475427T1 (en)
AU (2) AU2001251546B9 (en)
BR (1) BR0110030A (en)
CA (3) CA2406367C (en)
CY (2) CY1108065T1 (en)
DE (6) DE60143549D1 (en)
DK (6) DK1604680T3 (en)
ES (7) ES2353878T3 (en)
MX (1) MXPA02009932A (en)
NZ (1) NZ521535A (en)
PT (2) PT1604680E (en)
TW (1) TWI282282B (en)
WO (1) WO2001078760A2 (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) † 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (en) * 2001-01-05 2002-07-05 Univ Degli Studi Udine USE OF BOTULIN TOXIN FOR THE SOLUTION OF JOINT PATHOLOGIES, IN PARTICULAR OF COXARTROSIS, EPICONDYLITIS AND PATHOLUS
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (en) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 Granular composition and method for producing the same
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
EP1443932B1 (en) 2001-11-15 2012-12-26 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2002317127A1 (en) * 2002-07-19 2004-02-09 Mestex Ag Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
KR20050061541A (en) * 2002-10-15 2005-06-22 알러간, 인코포레이티드 Botulinum toxin dental therapies and procedures
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
KR20050109969A (en) * 2003-03-06 2005-11-22 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
CN1997373B (en) * 2004-05-07 2010-12-22 菲特托克斯有限公司 Phycotoxins and uses thereof
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
KR100668570B1 (en) 2004-06-28 2007-01-16 입센 리미티드 Pharmaceutical Composition Comprising Botulinum Toxin for Treating Knee Joint Pain by Saphenous Nerve Entrapment
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1982996A1 (en) 2004-09-01 2008-10-22 Allergan, Inc. Degradable clostridial toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2006034404A2 (en) 2004-09-23 2006-03-30 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (en) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic USE OF BOTULINUM TOXIN FOR PROLONGED LOCAL INSENSITION
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
KR20070116710A (en) 2005-03-03 2007-12-11 알러간, 인코포레이티드 Animal product free system and process for purifying a botulinum toxin
AU2006225116B2 (en) 2005-03-15 2012-04-19 Allergan, Inc. Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
EP2264458A1 (en) 2005-04-05 2010-12-22 Allergan, Inc. Clostridial toxin activity assays
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
EP1898947A2 (en) * 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
BRPI0613631A8 (en) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsion and method,
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
PT3295955T (en) 2005-12-01 2021-07-12 Univ Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (en) * 2006-05-19 2011-03-23 清华大学 Detector array and its apparatus
FR2902341B1 (en) 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (en) * 2006-10-27 2012-12-28 Scras THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN INDUCED BY AT LEAST ONE ANTI-CANCER AGENT
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
JP5292304B2 (en) 2006-12-01 2013-09-18 アンテリオス， インコーポレイテッド Peptide nanoparticles and uses thereof
BRPI0719756A2 (en) 2006-12-01 2014-01-21 Anterios Inc Amphiphilic Nanoparticles
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS.
EP2117584B1 (en) * 2007-02-15 2013-10-09 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder disorders
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DE102007038015A1 (en) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Use of a neurotoxin
JP2009132672A (en) * 2007-10-31 2009-06-18 Okayama Univ Pharmaceutical composition containing polypeptide derived from botulinum toxin as active component and having analgesic action
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
ES2356883B1 (en) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
US20100034853A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
US20100112005A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
EP2403522B1 (en) 2009-03-06 2015-12-16 Allergan, Inc. Clostridial toxin to improve ejaculate
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
CA2787062C (en) * 2010-01-26 2017-07-11 Michael A. Evans Methods, devices, and agents for denervation
JP2011157331A (en) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst Botulinus toxin formulation capable of high-dose administration
US20120195878A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
EP2729163A1 (en) 2011-07-08 2014-05-14 Allergan, Inc. Method for treatment of autonomic nervous system disorders
KR20140054055A (en) 2011-07-14 2014-05-08 알러간, 인코포레이티드 Methods for treatment of incontinence associated with sexual activity
MX2014000612A (en) 2011-07-20 2014-02-27 Allergan Inc Botulinum toxins for use in a method for treatment of adipose deposits.
ES2424294B1 (en) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
ES2660901T3 (en) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compounds that inhibit neuronal exocytosis (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
EP2976060B1 (en) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
AU2015315571A1 (en) * 2014-09-12 2017-04-27 Allergan, Inc. Methods for treating osteoarthritis pain
HUE053935T2 (en) 2015-01-09 2021-08-30 Ipsen Bioinnovation Ltd Cationic neurotoxins
EP3355938B1 (en) 2015-10-01 2024-02-07 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
CN117731591A (en) 2016-11-21 2024-03-22 艾里奥治疗公司 Transdermal delivery of large agents
US11623000B2 (en) 2017-05-24 2023-04-11 Atgc Co., Ltd. Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
JP7186228B2 (en) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド Use of ultrasound to guide injection of non-cytotoxic proteases
LT3660509T (en) 2018-11-29 2022-05-10 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030431A1 (en) * 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
WO1996033273A1 (en) * 1995-04-21 1996-10-24 The Speywood Laboratory Limited Botulinum toxin derivatives able to modify peripheral sensory afferent functions
WO1997034624A1 (en) * 1996-03-20 1997-09-25 Allergan Sales, Inc. Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693207B1 (en) * 1992-07-03 1994-09-30 Orsan Yeast strain allowing the co-expression of a heterogeneous cytochrome P450 monooxygenase activity and an endogenous or heterologous NADPH-cytochrome P450-reductase and its use for bioconversion purposes.
EP0679090A1 (en) 1993-01-15 1995-11-02 Interactive Biologics Associates Method for treating myofascial pain syndrome
US5592212A (en) * 1993-04-16 1997-01-07 News Datacom Ltd. Methods and systems for non-program applications for subscriber television
ES2319860T3 (en) * 1993-12-28 2009-05-14 Allergan, Inc. USE OF TYPE B BOTULIN TOXIN FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO REDUCE THE PAIN ASSOCIATED WITH A MUSCLE DISORDER.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JPH08306853A (en) * 1995-05-09 1996-11-22 Fujitsu Ltd Semiconductor device, manufacture thereof and manufacture of lead frame
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2006017004A1 (en) 2004-07-07 2006-02-16 Obstecare Inc. Method for monitoring a childbirth process

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030431A1 (en) * 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
WO1996033273A1 (en) * 1995-04-21 1996-10-24 The Speywood Laboratory Limited Botulinum toxin derivatives able to modify peripheral sensory afferent functions
WO1997034624A1 (en) * 1996-03-20 1997-09-25 Allergan Sales, Inc. Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARRUTHERS A ET AL: "Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections.", HEADACHE, vol. 39, no. 9, October 1999 (1999-10-01), pages 662 - 665, XP001031356 *
DIAZ J H ET AL: "Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin.", ANESTHESIOLOGY, vol. 91, no. 3, 1999, pages 877 - 879, XP001031347 *
GÖBEL H ET AL: "Evidence-based medicine: Botulinum toxin A in migraine and tension-type headache.", JOURNAL OF NEUROLOGY, vol. 248, no. Suppl. 1, April 2001 (2001-04-01), pages I/34 - I/38, XP002182693 *
GUYER B M: "Mechanism of botulinum toxin in the relief of chronic pain", CURRENT REVIEW OF PAIN, vol. 3, 1999, pages 427 - 431, XP001031379 *
SILBERSTEIN S ET AL: "Botulinum toxin type A as a migraine preventive treatment.", HEADACHE, vol. 40, no. 6, June 2000 (2000-06-01), pages 445 - 450, XP002182692 *

Also Published As

Publication number Publication date
TWI282282B (en) 2007-06-11
EP1550456B1 (en) 2012-09-26
DK1604680T3 (en) 2010-05-10
ATE475427T1 (en) 2010-08-15
NZ521535A (en) 2004-09-24
US20050152925A1 (en) 2005-07-14
JP4037652B2 (en) 2008-01-23
US7361358B2 (en) 2008-04-22
US20050058666A1 (en) 2005-03-17
DE60128899T2 (en) 2008-02-21
EP1272207B1 (en) 2007-06-13
CA2406367C (en) 2008-01-29
CN1188165C (en) 2005-02-09
DE60143061D1 (en) 2010-10-21
EP1604680B1 (en) 2010-01-27
CA2485920A1 (en) 2001-10-25
US20070014816A1 (en) 2007-01-18
ES2338238T3 (en) 2010-05-05
ES2353878T3 (en) 2011-03-07
ATE489102T1 (en) 2010-12-15
US20040018214A1 (en) 2004-01-29
US7172763B2 (en) 2007-02-06
DE60141230D1 (en) 2010-03-18
US7294339B2 (en) 2007-11-13
JP2003531127A (en) 2003-10-21
US7276245B2 (en) 2007-10-02
US20060275326A1 (en) 2006-12-07
KR20030009431A (en) 2003-01-29
ES2394314T3 (en) 2013-01-30
US20060039916A1 (en) 2006-02-23
US7374769B2 (en) 2008-05-20
US20060039917A1 (en) 2006-02-23
US7291344B2 (en) 2007-11-06
ATE480253T1 (en) 2010-09-15
ES2349782T3 (en) 2011-01-11
US20040028706A1 (en) 2004-02-12
EP1550456A3 (en) 2005-12-07
DK1576963T3 (en) 2011-02-21
ES2287117T3 (en) 2007-12-16
CY1109972T1 (en) 2014-09-10
ATE364393T1 (en) 2007-07-15
US7067137B2 (en) 2006-06-27
EP1604679A1 (en) 2005-12-14
AR030209A1 (en) 2003-08-13
US7211262B2 (en) 2007-05-01
EP1576963A2 (en) 2005-09-21
EP1576963A3 (en) 2005-12-07
DK1604679T3 (en) 2010-10-25
WO2001078760A2 (en) 2001-10-25
DK1604681T3 (en) 2010-11-29
PT1272207E (en) 2007-06-29
US7288260B2 (en) 2007-10-30
DE60142590D1 (en) 2010-08-26
ATE456375T1 (en) 2010-02-15
US6869610B2 (en) 2005-03-22
EP1604681A1 (en) 2005-12-14
US7468189B2 (en) 2008-12-23
EP1604679B1 (en) 2010-07-28
US6464986B1 (en) 2002-10-15
CN1436085A (en) 2003-08-13
ES2347256T3 (en) 2010-10-27
BR0110030A (en) 2003-06-03
DK1272207T3 (en) 2007-09-10
EP1604678B1 (en) 2010-07-14
CA2406367A1 (en) 2001-10-25
US20080138364A1 (en) 2008-06-12
CA2485919A1 (en) 2001-10-25
DK1604678T3 (en) 2010-10-18
EP1604681B1 (en) 2010-09-08
US20060275325A1 (en) 2006-12-07
MXPA02009932A (en) 2004-08-19
ATE473753T1 (en) 2010-07-15
EP1576963B1 (en) 2010-11-24
ES2347792T3 (en) 2010-11-04
DE60143549D1 (en) 2011-01-05
US20020176872A1 (en) 2002-11-28
AU2001251546B9 (en) 2004-12-02
EP1272207A2 (en) 2003-01-08
PT1604680E (en) 2010-02-11
CY1108065T1 (en) 2014-02-12
EP1604678A1 (en) 2005-12-14
DE60142712D1 (en) 2010-09-09
EP1550456A2 (en) 2005-07-06
US20040018213A1 (en) 2004-01-29
AU5154601A (en) 2001-10-30
EP1604680A1 (en) 2005-12-14
US20040018212A1 (en) 2004-01-29
AU2001251546B2 (en) 2004-07-01
DE60128899D1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2001078760A3 (en) Method for treating pain by peripheral administration of a neurotoxin
WO2001095924A3 (en) Method for treating a movement disorder
WO2001026736A3 (en) Intraspinal compositions containing botulinum toxin for treating pain
AU2001251546A1 (en) Method for treating pain by peripheral administration of a neurotoxin
DE60323628D1 (en) INTRAKRANIAL TREATMENT OF NEUROPSYCHIATRIC DISEASES WITH CLOSTRIDIUM NEUROTOXINES SUCH AS BOTULINUS TOXIN
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
WO2002028425A3 (en) Methods for treating muscle injuries
WO2001062270A3 (en) Method for treating hashimoto's thyroiditis
WO2001082961A3 (en) Methods for treating bone tumors
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
TW200503751A (en) Methods for treating sinus headache
WO2002053177A3 (en) Agents and methods for treating pain
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2005046618A3 (en) Methods of treating eczema
WO2001060347A3 (en) Method for treating ocular pain
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2719162C (en) Methods of treating acne
DE60310400D1 (en) BOTULINUS TOXINE FOR THE TREATMENT OF PRIAPISM
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
DK1383540T3 (en) Methods and pharmaceutical compositions for wound healing
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
WO2005030123A3 (en) Botulinum antitoxin compositions and methods
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 521535

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001251546

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009932

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027013536

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 576060

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001924939

Country of ref document: EP

Ref document number: 2406367

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018109454

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001924939

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027013536

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 521535

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001251546

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 521535

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001924939

Country of ref document: EP